Tel：
(86)(21)60969600
Add: Building 28, Lane 588, Tianxiong Road. Shanghai, P. R. China
Shanghai, China – On May 18, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort EP") obtained the registration certificate of China Food and Drug Administration ("CFDA") for its in-house developed ColumbusTM 3D EP Navigation System (2.0).
As the first domestic magnetic navigation system, ColumbusTM uses delicate catheters to map atriums and ventricles. With self-developed mapping/ablation catheters and reference patch from MicroPort EP, system can show real-time 3D images of cardiac chambers after collecting and analyzing electrophysiological activities. Compared to ColumbusTM (1.0), the 2.0 model has more convenient and efficient clinical functions: (1) Rapid modeling; Real-time mapping (RTM); (2) Multi-catheter display, multiple positioning catheters can be displayed at the same time; (3) Multi-events recording, to view records of ablation events, stimulation events, and etc during produces; (4) Foot pedaling, to facilitate the physician's operation.
ColumbusTM (1.0) gained the CE certificate in 2013, and it is the only domestically made 3D EP navigation system with the CE certificate. In 2016, ColumbusTM(1.0) was granted the CFDA approval. With the CFDA approval of ColumbusTM (2.0), it will provide more safe, effective, and affordable solution for patients with arrhythmias. As the only domestic company that provides a complete solution of cardiac EP treatment, MicroPort EP will continue to strive for innovation and perfection to provide better arrhythmia solutions for patients and physicians.
